CSL Response to Patent Complaint
FY2017 profit upgrade CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims.

Half Year Result 20171
Half Year Results Announcement 2017 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP).

Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
Study Published in Cell Metabolism

Melbourne, 10 February, 2017 04.00AM AEDT: An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes.


All News Releases >

Media Resources

CSL Behring Company Information
CSL Company Information >
CSL Behring Media Contacts
CSL Media
Contacts >
CSL Behring Social Media
CSL Social
Media >
CSL Behring MultiMedia Library
CSL Media
Library >

© 2017 CSL Limited